MapLight Therapeutics (MPLT) Profit After Tax (2024 - 2025)
MapLight Therapeutics (MPLT) reported Profit After Tax of -$79.5 million for Q4 2025, down 274.71% on a YoY basis from $45.5 million in Q4 2024, and down 170.37% sequentially from -$29.4 million in Q3 2025.
MapLight Therapeutics (MPLT) Profit After Tax (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Profit After Tax data on file, last reported at -$79.5 million in Q4 2025.
- For the quarter ending Q4 2025, Profit After Tax fell 274.71% year-over-year to -$79.5 million; the trailing twelve-month figure through Dec 2025 stood at -$149.2 million (changed N/A YoY), and the FY2025 full-year result was -$161.2 million, down 107.72% from the prior year.
- Profit After Tax eased to -$79.5 million in Q4 2025, from -$29.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$19.0 million in Q3 2024 to a low of -$79.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | -79.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79.55 Mn |
| Sep 30, 2025 | -29.42 Mn |
| Dec 31, 2024 | -21.23 Mn |
| Sep 30, 2024 | -19.02 Mn |